

-	
Hijtjert Greene Sterne	Patrick El Garrett
t dward il Kessler	jeHery * Heisey+
unge Allippidaten	Held i Krau
Javid K.S. Cott Avi	Casta Cibardo
Rusert Wilsonur i	Edward Alinne
Paul Let el Gradik tr	Albert Liferri
Michele Alicimbala	lumad∺ Bark∙
Michael Bi Ray	Keter Aliau≉nia
Notiert E. Nokoth	Mely A. Micia
Eric K. Steffe	Teresa 👉 Medler
Michael Dillee	jeffrey S. Weaver
Steven house IV-1	Kendriuk <sup>Di P</sup> atter
ut Michett	and type for
ur da El Allorr	Albert Lifaku L
Rateria Mijang	Ejdora Elisor Fil
Jawrence Bi Bugaisky	A 82556 14 13
Luna di Feathérstone	Thomas y Flata
Michael V Messinger	Brani, Dej Buyr
judith a Kim	yrgillee Beasta
Smothy a Shear it	Reginald Discusa

April 18, 2002

WRITER'S DIRECT NUMBER: (202) 371-2560 INTERNET ADDRESS: resmond a skgf.com

Commissioner for Patents Washington, D.C. 20231

> U.S. Utility Patent Application Re:

> > Appl. No. 09/937,484; § 371 Date: January 23, 2002

Use of a Lectin or Conjugates for Modulation of C-Fibre Activity

Inventors: Foster et al.

Our Ref: 1581.0870000/RWE/MTT

Sir:

Transmitted herewith for appropriate action are the following documents:

- First Supplemental Information Disclosure Statement: 1.
- Form PTO-1449 and accompanying reference: 2.
- Certificate Under 37 C.F.R. § 3.73(b), with copy of Assignment attached (which 3. was erroneously returned to the undersigned together with the recorded Assignment) to be made of record in the application file; and
- Return postcard. 4.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents April 18, 2002 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted.

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond Attorney for Applicants Registration No. 32.893

RWE/dab Enclosures

SKGL DC1 4477 L



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Foster et al.

Appl. No. 09/937,484

§ 371 Date: January 23, 2002

For: Use of a Lectin or Conjugates for

**Modulation of C-Fibre Activity** 

Confirmation No. 2134

Art Unit: (to be assigned)

Examiner: (to be assigned)

Atty. Docket: 1581.0870000/RWE/MTT

## First Supplemental Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on September 26, 2001, in connection with the above-captioned application. A copy of the document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Consideration of the cited document and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond

Attorney for Applicants Registration No. 32,893

butw Somm

Date:

April 18,2002

1100 New York Avenue, N.W. Suite 600

Washington, D.C. 20005-3934

(202) 371-2600

SKGE DC1 4382.1

Page 1 of 1 APPLICATION NO. ATTY. DOCKET NO. 1581.0870000/RWE/MTT 09/937,484 FORM PTO-1449 APPLICANTS Foster et al. TION DISCLOSURE STATEMENT § 371 DATE GROUP January 23, 2002 (to be assigned) PATENT DOCUMENTS EXAMINER DOCUMENT DATE NAME CLASS SUB-FILING DATE INITIAL CLA NUMBER AA AB АC ΑD ΑE AF AG АН ΑI АJ ΑK FOREIGN PATENT DOCUMENTS EXAMINER DOCUMENT DATE COUNTRY CLASS SUB-TRANSLATION INITIAL CLASS NUMBER Yes No ALYes No ΑM Yes No AN Yes No ΑO Yes No ΑP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Bizzini, B., "Investigation of the Mode of Action of Tetanus Toxin With the Aid of Hybrid Molecules Consisting in Part of Tetanus Toxin-Derived Fragments," in AR Bacterial Frotein Toxins, Academic Press London, pp. 427-434 (1984) AS AT 7 EXAMINER DATE CONSIDERED **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609.

line through citation if not in conformance and not considered. Include copy of this form with next

communication to Applicant.